Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia

Lancet

Volumn 351, Issue 9102, 1998, Pages 550-554

  Coustan Smith, Elaine ^a   Behm, Frederick G ^a   Sanchez, Joaquin ^a   Boyett, James M ^a   Hancock, Michael L ^a   Raimondi, Susana C ^a   Rubnitz, Jeffrey E ^a   Rivera, Gaston K ^a   Sandlund, J Torrey ^a   Pui, Ching Hon ^a   Campana, Dario ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TENIPOSIDE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW BIOPSY; CHEMOTHERAPY; CHILD; FLOW CYTOMETRY; GENE REARRANGEMENT; HUMAN; IMMUNOASSAY; INCIDENCE; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RELAPSE; SERODIAGNOSIS;

EID: 0347184138     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)10295-1     Document Type: Article

References (27)

1. 1 Pui C-H. Childhood leukemias. N Engl J Med 1995; 332: 1618-30.
2. 2 Campana D, Pui C-H. Detection of minimal residual disease in acute leukemia: methodological advances and clinical significance. Blood 1995; 85: 1416-34.
3. 3 Wasserman R, Galili N, Ito Y, et al. Residual disease at the end of the induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. J Clin Oncol 1992; 10: 1879-85.
4. 4 Brisco MJ, Condon J, Hughes E, et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994; 343: 196-200.
5. 5 Jacquy C, Delepaut B, Van Daele S, et al. A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse. Br J Haematol 1997; 98: 140-46.
6. 6 Neale GAM, Menarguez J, Kitchingman GR, et al. Detection of minimal residual disease in T-cell acute lymphoblastic leukemia using polymerase chain reaction predicts impending relapse. Blood 1991; 78: 739-45.
7. 7 Biondi A, Yokota S, Hansen-Hagge TE, et al. Minimal residual disease in childhood acute lymphoblastic leukemia: analysis of patients in continuous complete remission or with consecutive relapse. Leukemia 1992; 6: 282-88.
8. 8 Nizet Y, Van Daele S, Lewalle P, et al. Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IgH probes and the polymerase chain reaction. Blood 1993; 82: 1618-25.
9. 9 Kitchingman GR. Residual disease detection in multiple follow-up samples in children with acute lymphoblastic leukemia. Leukemia 1994; 8: 395-402.
10. 10 Cave H, Guidal P, Rohrlich P, et al. Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of omega and gamma T-cell receptor genes. Blood 1994; 83: 1892-901.
11. 11 Seriu T, Yokota S, Nakao M, et al. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation. Leukemia 1995; 9: 615-23.
12. 12 Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med 1997; 336: 317-23.
13. 13 Cross NCP. Quantitative PCR techniques and applications. Br J Haematol 1995; 89: 693-97.
14. 14 Beishuizen A, Verhoeven M-AJ, van Wering ER, Hahlen K, Hooijkaas H, van Dongen JJM. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis. Blood 1994; 83: 2238-47.
15. 15 Steward CG, Goulden NJ, Katz F, et al. A polymerase chain reaction study of the stability of Ig heavy-chain and T-cell receptor omega gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia. Blood 1994; 83: 1355-62.
16. 16 Steenbergen EJ, Verhagen OJHM, Van Leeuwen EF, et al. Frequent ongoing TCR delta rearrangements in childhood precursor acute lymphoblastic leukemia: implications for monitoring minimal residual disease. Blood 1995; 86: 692-702.
17. 17 Pui C-H, Boyett JM, Hughes WT, et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 1997; 336: 1781-87.
18. 18 Pui C-H, Rivera GK, Hancock ML, et al. Risk-adapted treatment for acute lymphoblastic leukemia: findings from St Jude Children's Research Hospital. In: Buchner T, Hiddeman W, Wormann B, Schellong G, Ritter J, Crentzig U, eds. Acute leukemia VI: prognostic factors and treatment strategies; haematology and blood transfusions. Berlin:Springer-Verlag, 1997: 629-37.
19. 19 Campana D, Coustan-Smith E, Janossy G. The immunological detection of minimal residual disease in acute leukemia. Blood 1990; 76: 163-69.
20. 20 Coustan-Smith E, Behm FG, Hurwitz CA, et al. N-CAM (CD56) expression by CD34+ malignant myeloblasts has implications for minimal residual disease detection in acute myeloid leukemia. Leukemia 1993; 7: 853-58.
21. 21 Orfao A, Ciudad J, Lopez-Berges MC, et al. Acute lymphoblastic leukemia (ALL): detection of minimal residual disease (MRD) by flow cytometry. Leuk Lymph 1994; 13: 87-90.
22. 22 Vervoordeldonk SF, Merle PA, Behrendt H, et al. Triple immunofluorescence staining for prediction of relapse in childhood B acute lymphoblastic leukemia. Br J Haematol 1996; 92: 922-28.
23. 23 Sang BC, Shi L, Dias P, et al. Monoclonal antibodies specific to the acute lymphoblastic leukemia t(1;19)-associated E2A/pbx1 chimeric protein: characterization and diagnostic utility. Blood 1997; 89: 2909-14.
24. 24 Behm FG, Smith FO, Raimondi SC, et al. Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemia with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. Blood 1996; 87: 1134-39.
25. 25 Menssen HD, Renkl HJ, Rodeck U, et al. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995; 9: 1060-67.
26. 26 Coustan-Smith E, Kitanaka A, Pui C-H, et al. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood 1996; 87: 1140-46.
27. 27 Ito Y, Wasserman R, Galili N, et al. Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphoblastic leukemia. J Clin Oncol 1993; 11: 546-50.